Total Clarity Wealth Management Inc. Purchases 156 Shares of Amgen Inc. (NASDAQ:AMGN)

Total Clarity Wealth Management Inc. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,018 shares of the medical research company’s stock after purchasing an additional 156 shares during the period. Total Clarity Wealth Management Inc.’s holdings in Amgen were worth $2,350,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the 3rd quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the 3rd quarter worth approximately $29,000. Matrix Trust Co bought a new position in shares of Amgen during the 3rd quarter worth approximately $36,000. Heck Capital Advisors LLC bought a new stake in shares of Amgen in the 4th quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of Amgen in the 3rd quarter worth approximately $56,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 0.5 %

NASDAQ:AMGN opened at $285.42 on Friday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a market cap of $153.42 billion, a PE ratio of 36.55, a price-to-earnings-growth ratio of 2.85 and a beta of 0.56. The company has a 50 day simple moving average of $271.24 and a two-hundred day simple moving average of $304.84.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter last year, the company posted $4.96 EPS. The company’s revenue was up 23.2% compared to the same quarter last year. Research analysts forecast that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.34%. Amgen’s payout ratio is 115.24%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on AMGN shares. Citigroup lowered their price target on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a report on Tuesday. Redburn Partners reduced their price objective on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. UBS Group reduced their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, October 31st. Truist Financial reduced their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research note on Wednesday, January 8th. Finally, TD Cowen lifted their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.